Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Rare Tumors|October 3, 2014
The rare cancer network: ongoing studies and future strategyMahmut Ozsahin, René-Olivier Mirimanoff, Juliette Thariat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative GroupJean-Marc Tourani, Christian Pfister, Nicole Tubiana, et al.International Journal of Radiation Oncology, Biology, Physics|November 29, 2024
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABRJuliette Thariat, Mathieu Bosset, Antoine Falcoz, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 20, 2024
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trialChristian Borel, Xu-Shan Sun, Alexandre Coutte, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 18, 2020
Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trialYungan Tao, Anne Auperin, Pierre Blanchard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2018
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized TrialYungan Tao, Anne Auperin, Christian Sire, et al.Cancers|June 2, 2021
Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown PrimaryYazan Abu-Shama, Julia Salleron, Florent Carsuzaa, et al.The Lancet. Healthy Longevity|February 19, 2026
Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trialCécile Ortholan, Anne Aupérin, Yungan Tao, et al.European Journal of Cancer (Oxford, England : 1990)|March 4, 2019
Unilateral or bilateral irradiation in cervical lymph node metastases of unknown primary? A retrospective cohort studyCarole Pflumio, Idriss Troussier, Xu Shan Sun, et al.The Lancet. Oncology|August 8, 2020
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 studyXu-Shan Sun, Yungan Tao, Christophe Le Tourneau, et al.Pageof 3